{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-059541","form_type":"8-K","ticker":"SMNR","cik":"0001913577","company_name":"Semnur Pharmaceuticals, Inc.","filed_at":"2024-07-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.187670+00:00","generated_at":"2026-05-31T23:25:00.195812+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Denali Capital SPAC signs LOI to combine with Semnur Pharma at up to $2B valuation","bullets":["Pre-transaction equity value of Semnur up to $2.0B, subject to third-party fairness opinion adjustment.","Expected cash on hand at closing up to $40M depending on SPAC share redemptions.","Combined company to focus on SP-102 (SEMDEXA), a non-opioid epidural gel for sciatica with FDA Fast Track status.","Scilex Holding (Nasdaq: SCLX) expected to be majority holder of the combined company.","Parties anticipate seeking SPAC shareholder approval in second half of 2024; no definitive agreement yet."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-059541","json":"https://secwatch.observer/filing/0001213900-24-059541.json","markdown":"https://secwatch.observer/filing/0001213900-24-059541.md","text":"https://secwatch.observer/filing/0001213900-24-059541.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1913577/000121390024059541/0001213900-24-059541-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1913577/000121390024059541/ea0208972-8k_denali.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:25:00.195812+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}